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1. Introduction 
Gestational Diabetes Mellitus (GDM) bring repercussions not only during pregnancy and 
delivery, but also in the future, with implications for Public Health. Nonetheless, after 
delivery, there is a tendency of the health team and medical institutions to relax the care 
given to women with GDM, probably due to the fact that their blood glucose values usually 
return rapidly to their normal level, wasting in this way the opportunity of preserving the 
health status of these relatively young group of women with a high risk of cardiovascular 
events, greatly due to the subsequent development of type 2 diabetes (Bentley-Lewis, 2009; 
Shah et al., 2008). In recent years an increase in the prevalence of GDM in different 
populations and ethnic groups has been observed (Dabelea et al., 2005; Hunt & Schuller, 
2007). Being GDM, very frequently, a diabetes precursor, a large number of fertile women 
will be increasingly subjected to a higher risk of developing it in a variable time, generally 
during middle age. This implies a long period of potential risk for chronic micro and 
macroangiophatic complications, with implied high social and economical costs. 
Women with GDM constitute an excellent target for applying diabetes preventive measures 
and its comorbidities. In this sense, a continuous and prolonged post-partum follow-up is 
recommended with two main objectives: to implement non-pharmacological and 
pharmacological preventive measures, whose efficiency has  been shown in some studies 
(Buchanan et al., 2002; Ratner et al., 2008), and also to carry out early detection of diabetes 
and other cardiovascular risk factors by guidelines that unfortunately, vary from one 
organization to another (Asociación Latinoamericana de Diabetes (ALAD), 2008: Metzger et 
al., 2007: National Institute for Health and Clinical Excellence (NICE), 2008), partly 
explaining low compliance rates and short duration of follow-ups, even in developed 
countries (Blatt et al., 2011; Dinh et al., 2003; Ferrara et al., 2009; Kim et al., 2007a). Moreover, 
maternal breastfeeding stimulus and the most adequate contraceptive method are included 
(Kim, 2009, 2010; Kitzmiller et al., 2007). More recently, the association between GDM with 
periodontal disease has been demonstrated, therefore it was considered pertinent to include 
oral health measures (Friedlander et al., 2007; Novak et al., 2006).  
During pregnancy, women with GDM require education under the premise that glucose 
intolerance is not always transitory, but that at any time after delivery it can become 
permanent, in order to increase awareness of the importance of postpartum follow-up, 
during which educational strategies aimed at correcting knowledge deficits on healthy life-
styles are studied in-depth (Rivas et al., 2010a); moreover, to overcome difficulties found in 
substituting inadequate habits in practice (Smith et al., 2005; Stage et al., 2004). To do so, it 
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seems essential to incorporate profound changes in the quality of life of the population that 
favor individual life-style changes. However, for a postpartum follow-up program to be 
successful, it is also important to amend existing weaknesses regarding knowledge and 
motivation of the interdisciplinary team responsible for health care in this area (Almario et 
al., 2008; Clark et al., 2003), and also, to provide health care services with easy access for all 
women with previous GDM (Kim et al., 2007a). 
This chapter will expound on focusing the future risks of women with GDM, as well as the 
basic aspects regarding early detection and prevention of diabetes and other cardiovascular 
risk factors. 
2. Maternal risks 
Maternal GDM repercussions in the future include an increased risk of developing GDM in 
subsequent pregnancies (Moses, 1997a), type 2 diabetes (Kim et al., 2002) and other 
cardiovascular risk factors such as obesity (Yun et al., 2007), dyslipidemia (Meyer-Seifer, 
1996) and hypertension (Gonçalves et al., 2005), which show up isolated or grouped in the 
Metabolic Syndrome (Madarász et al., 2008). Generally, they are accompanied by some 
degree of vascular, fibrinolytic and inflammatory dysfunction (Farhan et al., 2006¸ Heitritter, 
2005). Furthermore, the risk of other clinical conditions like polycystic ovary (PCO) (Kousta 
et al., 2000), periodontal disease (Xiong et al., 2006) and depression (34 Kozhimannil et al., 
2009) is increased (Table 1). 
 
• GDM in subsequent pregnancies  
• Type 1 diabetes  
• Type 2 diabetes 
• Metabolic Syndrome   
• Vascular abnormalities  
• Cardiovascular Disease 
• Polycystic ovaries  
• Periodontal Disease 
• Depression 
Table 1. Maternal Risks in women with Previous GDM 
2.1 GDM in subsequent pregnancies 
GDM recurrence occurs due to an abnormal glucose tolerance state that aggravates 
primarily due to physiological demands and hormonal changes of pregnancy itself, but may 
also show the presence of type 2 diabetes, that was not diagnosed between pregnancies, 
since a postpartum diabetes screening was not carried out. 
GDM recurrence rates in subsequent pregnancies show contradictory results, varying in 
different studies according to the population studied, GDM diagnostic criteria used, 
diabetes postpartum screenings and the exclusion or not of the preexisting diabetes 
proportion. In a review, it was found that they ranged from 30 and 84%, being White 
women rates <40% and in other ethnic groups that include African-American, Latin-
American an Asian women >50%, constituting ethnic group different from Caucasian, the 
most consistent predictor of GDM recurrence (Kim et al., 2007b).Other associations have 
been reported with GDM recurrence such as fat intake (Moses et al., 1997b), pre-pregnancy 
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maternal weight (Macneill et al., 2001) and the presence of impaired fasting glucose (IFG) or 
impaired glucose tolerance (IGT) in two-month postpartum screenings (Kwak et al., 2008).  
GDM risk in a second pregnancy has been found nearly ten-folds higher among women 
with previous GDM than in women without this family history, 41.3% and 4.2%, 
respectively. The risk increases with the number of previous GDM episodes and thus, with 
the third pregnancy, GDM recurrence was more marked when GDM had been diagnosed 
during the two previous pregnancies (Getahun et al., 2010).  
A new GDM pregnancy is not associated itself to a risk increase of type 2 diabetes in women 
with GDM history (Russel et al., 2008). Nonetheless, the absence of recurrent GDM in a 
subsequent pregnancy may show a decrease in the risk of developing type 2 diabetes   
(Retnakaran et al., 2011). 
2.2 Diabetes  
There is strong evidence proving that women with GDM show a high risk of developing 
diabetes through their lives (Damm et al., 2003). Even though the highest frequency 
corresponds to type 2 diabetes, type 1 diabetes may also occur, whose proportion will vary 
depending on the population studied (Järvelä et al., 2006). 
2.2.1 Type 1 diabetes  
For many decades GDM has been acknowledged as a heterogeneous alteration, where 
autoimmunity against beta cells constitutes the pathogenic basis in a small group of 
patients, who show a higher risk of developing type 1 diabetes during pregnancy or after 
delivery (Mauricio et al., 1996).  
In women with GDM, the determination of different specific antibodies against pancreatic 
beta cells, like antibodies to islet cells (ICA), glutamic acid decarboxilase antibodies 
(GADA), tyrosine phosphatase tyrosine (IA-2A), and most recently, GAD 65, proven pre-
clinical markers of type 1 diabetes (Mitchell et al., 2000; Murgia et al., 2008), has allowed to 
know that autoimmune GDM corresponds to 10% of GDM cases in Caucasian women and 
contributes to a peculiar and complex pre-diabetic state, with a high risk for progressing to 
type 1 diabetes and to a latent autoimmune diabetes of adulthood (LADA) (de Leiva et al., 
2007; Lapolla et al., 2009). The risk increases with the number of antibodies present 
(Füchtenbusch et al., 1997), and is higher during the first postpartum years (Nilsson et al., 
2007). In studies carried out on women with GDM that show positive antibodies, it was 
found that they were younger, showed lower body mass index (BMI), less proportion of 
family members with diabetes, less abdominal circumference, and lower levels of plasmatic 
insulin than in those women without antibodies. Moreover, they had gained less weight 
during pregnancy and had required insulin treatment in a higher proportion (Bo et al., 
2003). Non-Caucasian women with GDM have been less studied looking for autoimmune 
markers, being found in some cases, similar GADA incidence than in Caucasian women 
(Kousta et al., 2001), while in other studies, lower incidences have been obtained, but 
resulting likewise, the presence of antibodies against beta cells, an indicator of future type 1 
diabetes, even at early stages after delivery (Yu et al, 2009).  
The presence of antibodies in women with GDM shows immune-mediated pancreas 
destruction that causes a deficit in insulin secretion and development of type 1 diabetes. 
Therefore, the importance of making a type 1 diabetes diagnose as soon as possible, to apply 
therapeutic measures that allow preserving the endogenous insulin secretion and to reach 
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an adequate metabolic control that lowers the risk of poor pregnancy results (Wucher et al., 
2011) and of micro-vascular maternal complications in the future. Thus, in high risk 
populations of women with GDM, type 1 diabetes screenings must be carried out, looking 
for antibodies against beta cells. 
2.2.2 Type 2 diabetes 
Numerous epidemiological data suggest an association between GDM and type 2 diabetes, 
showing correspondence in both prevalences in a given population. These two disorders 
share metabolic aspects, risk factors and genetic susceptibility (Ben-Haroush et al., 2004).  
Physiopathological changes that occur in GDM, insulin resistance and the relative insulin 
deficiency due to the pancreatic beta cells deterioration, are similar to processes that occur in 
other pre-diabetic states of type 2 diabetes (Harlev & Wiznitzer, 2010) and they persist after 
pregnancy (Kousta et al., 2003). GDM and type 2 diabetes also have in common risk factors 
like BMI increase, family history of diabetes, increased age, Asian and African ethnic origin 
(Kim et al., 2002). Likewise, evidence has been gathered regarding that GDM susceptibility, as 
well as type 2 diabetes, has a genetic component where pregnancy could act as an 
environmental stressor that catalyses progression to a diabetic state in women with genetic 
predisposition. It is possible that both conditions are multigenic diseases in whose etiology 
interact variations of multiple genes with environmental factors, but no definite conclusions 
can yet be established, since the study on GDM genetics is on its initial stages and also because 
most researches have been carried out on a small group of White ethnic women (Robitaille & 
Grant, 2008), finding in some of them, that alleles associated to an increase of developing type 
2 diabetes, are elevated in women with previous GDM (Lauenborg et al., 2009). 
Cumulative incidence of type 2 diabetes varies widely in different reports, with a range of 
2.6 to 70% in studies that examined women between 6 weeks postpartum to 28 years 
postpartum (Kim et al., 2002. During the first months, glucose tolerance abnormalities in 
women with previous GDM were already found, showing diabetes prevalence rates  < 10% 
in White ethnic women (Pallardo et al., 1999; Feig et al., 2008) and ~10%, or higher in other 
ethnic groups (Kjos et al., 1990; Lin et al., 2005; Rivas et al., 2007). These rates most probably 
include women with type 2 diabetes, whose diagnosis had been unnoticed before 
pregnancy, being impossible to exclude them, due to the GDM definition used worldwide.  
Progress to diabetes is strong during the first years after delivery, with an annual rate of 5-
10%, reaching ~50% in five years, followed by a slower progression, and appearing a 
plateau after ten years (Kim et al., 2002; Wollitzer & Jovanovic, 2007). However, more recent 
studies show that postpartum risk of diabetes in women with DGM increases linearly 
through  the follow-up period, without indication of decrease after five years or plateau 
evidence of the incidence at ten years postpartum (Feig et al., 2008; Chodick  et al.,2010).  
It has been estimated that in women with GDM, the risk of developing type 2 diabetes along 
their lives is almost eight-fold higher than in those women who have not developed it 
(Chodick et al., 2010; Bellamy et al., 2009). In the well-known study Diabetes Prevention 
Program (DPP), women with GDM history showed a 74% increased hazard for developing 
diabetes than women without this history (17.1%/year compared to 9.8%/year, 
respectively) (Ratner et al., 2008) and, in Australia, it was found that 20-30% of women with 
type 2 diabetes refer previous GDM (Cheung & Byth, 2003). 
Several maternal risk factors have been associated to the conversion rate to diabetes, 
resulting highly predictive at short and long-term the oral glucose tolerance test (OGTT) 
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values during pregnancy, mainly, fasting plasma glucose (FPG) (Kim et al., 2002; Golden et 
al., 2009) and in lower proportion, 2-hour glucose values (Golden et al., 2009; Åberg et al., 
2002), area under OGTT curve (Golden et al., 2009; Weijers et al., 2006) and the number of 
OGTT abnormal values (Chodick et al., 2010). It has also been found that insulin therapy 
during pregnancy predicts future maternal diabetes (Chodick et al., 2010; Catalano et al., 
1991) and it is known that weight gain before, during and after pregnancy increases and 
accelerates the development of type 2 diabetes in women with previous GDM (Metzger et 
al,. 1993; Baptiste-Roberts et al., 2009; Xiang et al 2010). 
Other risk factors of type 2 diabetes in women with DGM have been reported, among them, 
age, non-Caucasian ethnicity, early GDM onset (Sinha et al,. 2003), length of postpartum 
period, deterioration of beta cell function and use of progestin-only contraception (Xiang et al 
2010, Xiang et al 2006a). A series of modifiable factors like low physical activity, low fruit and 
vegetable consumption, tobacco habits, low educational instruction, and low family income 
have also been found associated to the risk of type 2 diabetes in women with GDM history 
(Yun S et al., 2007). There is less knowledge on other risk factors of diabetes described in recent 
years in women with GDM, such as alteration of some inflammatory and fibrinolytic 
dysfunction markers, among them adiponectin decrease (Retnakaran et al. 2010), increase in C-
reactive protein (CRP) (Di Benedetto et al., 2005), homocysteine (Cho et al., 2005) and 
plasminogen activator inhibitor type 1 (PAI-1) (Morimitsu et al., 2007), among others. 
2.3 Metabolic syndrome and its components 
GDM is a marker for future development of type 2 diabetes and Metabolic Syndrome in the 
mother, currently acknowledging pregnancy as a window that reveals future metabolic and 
cardiovascular risks for the mother (Sattar & Greer 2002). 
Glucose tolerance abnormalities in postpartum have been associated to other components of 
the Metabolic Syndrome.  General obesity (Vohr & Boney, 2008), visceral obesity (Albareda 
et al,. 2005) and increases in body fat content, particularly visceral fat (Lim et al., 2007), are 
more frequent in women with GDM history compared to those in control groups. Also there 
is a higher risk of high blood pressure (Gonçalves  et al., 2005; Wender-Ozegowska  et al., 
2007) and impairment of lipid profile like high triglycerides and LDL-cholesterol values and 
low HDL-cholesterol values, even though some results are not always consistent (Wender-
Ozegowska et al., 2007; Meyers-Seifer & Vohr, 1996; Rivas et al., 2010b). Frequently, varying 
abnormalities are found both in insulin sensitivity as well as in the secretion function of 
pancreatic beta cells (Tura et al., 2008). 
The prevalence of the Metabolic Syndrome, regardless of the diagnostic criteria used, is 
three-fold higher in women with previous GDM than in women without this history and 
increases seven-fold in obese women (Lauenborg et al., 2005).  Pre-pregnancy obesity, OGTT 
fasting plasma glucose during index pregnancy and postpartum weight gain are predictors 
of developing Metabolic Syndrome (Akinci et al., 2010). 
2.4 Vascular abnormalities  
As in other high risk type 2 diabetes groups, in women with previous GDM, apart from 
abdominal obesity and insulin resistance, vascular abnormalities including impaired 
vascular reactivity, increased levels of some markers of endothelial activation, 
fibrinolysis/coagulation and low grade subclinical inflammation have been found 
(Caballero, 2005).  
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Among the reported vascular abnormalities are increase of peripheral vascular resistance 
(Heitritter et al., 2005) and impaired endothelium-dependent vasodilation, assessed at the 
brachial artery by high resolution ultrasound (Anastasiou etal., 1998), but this finding was 
not found in another study (Hannemann et al., 2002). On the other hand, serum adiponectin 
levels, an adipokine with known vascular effects, have been found to be lower in women 
with GDM during pregnancy and postpartum (Heitritter et al., 2005; Vitoratos et al., 2008a; 
Costacou et al., 2008). On the contrary, PAI-1 has been found elevated, considered as an 
expression of fibrinolytic dysfunction (Farhan et al., 2006), and of markers of low-grade sub-
clinical inflammation, Interleukin-1beta (IL-1β) has also been found elevated (Vitoratos et 
al., 2008b), whereas CRP shows contradictory results, since in some studies higher values 
have been obtained in women with previous GDM than in women with normoglycemic 
pregnancies (Heitritter et al., 2005; Di Cianni et al., 2007), no differences have been shown in 
other studies (Thomann et al., 2008) and in some, it is only significant the increase of CRP 
when diabetes has already been developed (Kim et al., 2008).  
2.5 Cardiovascular disease (CVD) 
As it has been described previously, women with previous GDM show in higher proportion, 
compared to women in control groups, numerous cardiovascular risk factors such as 
abdominal obesity, insulin resistance, abnormal glucose tolerance, dyslipidemia, high blood 
pressure values, Metabolic Syndrome, impairments of endothelial dysfunction and 
inflammation markers. For this reason, it has been proposed that these women have higher 
long-term probabilities of developing CVD (Bentley-Lewis, 2009), showing in an incidence 
research review that GDM history increases the risk of CVD about 1.7 folds (Verier-Mine, 
2010). This topic is of vital importance since CVD, and particularly, coronary artery disease, 
constitute one of the main causes of mortality and disability in different countries, thus its 
prevention and early identification in this group of young women may contribute to 
improve health indicators.  
2.6 Polycystic ovaries 
The prevalence of PCO has been found elevated in women with previous GDM, showing 
that both pathologies have common associations like obesity and insulin resistance (Kousta 
et al., 2000; Koivunen et al., 2001). 
2.7 Periodontal disease 
Women with GDM have shown higher frequency and severity of periodontal disease during 
pregnancy and postpartum than women without GDM, after controlling for age, income, 
smoking, dental calculus (Novak et al., 2006). The prevalence of periodontal disease in 
women with previous GDM is lower than in non-pregnant women with type 1 and 2 
diabetes, but higher than in non-diabetic women and without GDM family history (Xiong et 
al., 2006). A higher risk of dental caries also seems to exist (Friedlander et al., 2007).   
2.8 Stress, anxiety and depression 
Pregnancy generally represents an increase in stress and anxiety in all women, therefore, 
when GDM develops, considered as a high risk pregnancy demanding comprehensive 
treatment measures and monitoring of metabolic control, stress levels may increase even 
more (York et al., 1996). However, there are very few studies on this topic. On the other 
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hand, an association between diabetes during pregnancy and prenatal depression in low-
income women has been found (Kozhimannil et al., 2009), showing the importance of 
psycho-social aspects. 
3. Detection and prevention of diabetes and other cardiovascular risk factors 
Care for women with GDM is extended after delivery in order to assess at an early stage 
their new metabolic status, and more importantly, to take individual and collective 
measures that contribute to prevent or at least, retard the progression to diabetes and other 
cardiovascular risk factors. Thus, it is necessary that health services provide postpartum 
follow-up programs and motivate women with GDM to attend the activities programmed. 
Moreover, it is fundamental that the environment surrounding such women promotes life-
style changes that not only favor them, but also their family and the rest of the population.  
3.1 Postpartum follow-up of women with GDM 
For many years the importance of postpartum follow-up of women with GDM has been 
emphasized (Beischer et al., 1997). More recent findings suggest that it should be extended 
to women with any abnormal glucose homeostasis level during pregnancy (Retnakaran et 
al., 2008). Such a follow-up includes the aspects shown in Table 2. 
 
• Diabetes screening  
• Detection of cardiovascular risk factors     
• Education 
• Incentive and facilities for  breastfeeding   
• Appropriate family planning and contraception  
• Oral health measures 
• Life-style changes   
• Pharmacologic  intervention 
Table 2.  Postpartum Follow-up of women with GDM 
3.1.1 Diabetes screening 
During the immediate post-partum period of patients with GDM, glucose tests are run to 
detect those few cases where hyperglycemia persists, which mainly correspond to women 
whose type 2 diabetes had not been detected before pregnancy. The diabetes diagnose is 
confirmed if FPG is > 126 mg/dl (7.0 mmol/l) or if hyperglycemia symptoms and a random 
plasma glucose > 200 mg/dl (11.1 mmol/l) are present (American Diabetes Association 
(ADA), 2011). 
All those women not diagnosed with diabetes are programmed for a diabetes screening 
between weeks six and twelve of postpartum, due to a high incidence of glucose tolerance 
abnormalities already detected at that time and also because these results allow identifying 
women with high risks of developing diabetes during the next fifteen years (Kjos et al., 
1995). If diabetes screening is not possible at this time, it must be emphasized in the 
following weeks.  Diabetes screening is carried out with a 75g- 2h- OGTT, of higher 
sensitivity and less expensive per diabetes case detected than FPG (Ferrara et al., 2009; Kim 
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et al., 2007b). If the results are not compatible with diabetes diagnose, whether they are 
normal or indicators of IGT, or IFG, the test is repeated the following year and then, 
annually or every three years, according to the different international scientific associations 
since regarding periodicity of screening, no current criteria uniformity exists (Metzger et al., 
2007, American College of Obstetricians and Gynecologists (ACOG), 2009, Asociación 
Latinoamericana de Diabetes (ALAD), 2008). It is possible that HbA1c will be recommended 
in the future for postpartum diabetes screening in women with GDM, but studies on this 
test have not yet been published. 
3.1.2 Detection and treatment of cardiovascular risk factors 
Every time diabetes screenings are carried out, for detecting hypertension, obesity and 
dyslipidemias, women with previous GDM are determined for blood pressure, abdominal 
circumference, body mass index and triglyceride plasma levels, cholesterol, HDL-c and 
LDL-c. Determination of insulin levels, insulin-sensitivity indices, markers of endothelial 
activation, fibrinolysis/coagulation and low grade subclinical inflammation, and other 
specialized tests are optional in the clinical practice and are reserved in most cases, for 
research purposes. If the presence of any cardiovascular risk factor is confirmed, the 
corresponding therapeutic measures are prescribed.  
3.1.3 Education 
Education, initiated during pregnancy, constitutes the basis for GDM management. It is 
imparted in theoretical-practical sessions individually or in groups, whose content and 
strategies take into account the socio-economical and cultural characteristics of the enrolled 
women. At the postpartum stage, it is directed basically to imparting knowledge on future 
maternal risks and on their off-spring, as well as to the life-style changes that contribute to 
prevent or retard diabetes development and its co-morbidities.  It has been found that 
knowledge on these topics is limited in women with GDM, but increases after participating 
in an educational program imparted by specialized health personnel (Rivas et al., 2010a). 
3.1.4 Breastfeeding incentive and facilities 
As other women, women with GDM must be actively stimulated for exclusively 
breastfeeding for the longest period during the first year of their child (Metzger et al., 2007). 
But in this case, it is paramount to contribute in reducing subsequent risks of obesity and 
glucose tolerance abnormalities. Even though there is currently no definite conclusion on 
this (Gouveri et al., 2011), many studies show beneficial results of breastfeeding in women 
with GDM (Kjos et al., 1993; Gunderson et al., 2010). 
3.1.5 Appropriate family planning and contraception 
In women with GDM postpartum contraception is recommended (Metzger et al., 2007) in 
order to prevent a future unplanned pregnancy, with a high risk of developing once more 
GDM and where teratogenic effects of non-diagnosed diabetes may also be present. There is 
a wide option of contraceptive methods (Kim, 2009; Kim, 2010; Damm et al., 2007) that in 
general differ little from the ones used by other women. However, it is important to choose 
a contraceptive method that does not increase maternal risk of glucose intolerance, 
metabolic syndrome and CVD, as it occurs with barrier methods, the lactation amenorrhea 
method during the first six months and intrauterine devices (IUD), both copper and 
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levonorgestrel-releasing IUD, which possess known advantages and limitations. Low-dose 
combination oral contraceptives, with ethinyl estradiol and a progestin, may also be used, 
but they are not recommended for women that have other cardiovascular risk factors like 
hypertension. Even though family history of GDM does not mean contraindication of any 
method, progestin-only pills should be avoided in women who are breastfeeding, since in a 
study carried out on Latin-women it was found that it was associated to an increase of 
diabetes risk, assuming that breastfeeding may be a relatively progestagenic state (Kjos et 
al., 1998). Neither long-acting progestin methods like depot medroxyprogesterone acetate 
nor medroxyprogesterone, may be suggested as a first option since they may have major 
effects on the hydrocarbonated metabolism, as it was proven in Navajo women (Kim et al., 
2001). In parous women refraining from another pregnancy, surgical sterilization is a good 
option, particularly in those delivering by cesarean section, since sterilization may be 
practiced during surgical procedures. 
3.1.6 Oral health measures 
It is important that oral health measures proposed to the population in general for 
prevention of caries and periodontal disease, are rigorously adopted by women with 
previous GDM, who moreover, should visit at least annually the dentist in order to carry 
out an early diagnose of these complications when they arise and to apply the required 
therapeutic measures. The dentist will be on the alert to detect if progression to diabetes has 
occurred, contributing with this pathology screening (Friedlander et al., 2007). 
3.1.7 Life-style changes  
Childbearing years constitute one of the stages in the life of a woman more prone to weight 
gain. Thus, life-style changes make up the building blocks for the prevention of diabetes and 
other cardiovascular risk factors in women with GDM. Providing preventive care leading to 
reach and maintain an adequate weight, that include strategies on the aspects shown on 
Table 3, would result extremely beneficial for the health of this vulnerable population group 
and also cost-effective (Kapustin, 2008). Even though specific studies on this aspect are 
scarce and show limitations, it has been found that intensive intervention on life-style 
changes in women with previous GDM, reduced to a 50% diabetes incidence (Ratner et al., 
2008). Undoubtedly, there is a need to study in depth this topic.  
  
• Healthy nutrition  
• Physical activity 
• Non-smoking 
• Low to Moderate alcohol consume 
• Adequate stress management 
Table 3. Life-style changes in women with previous GDM 
3.1.7.1 Healthy nutrition 
In general, nutritional recommendations for women with a high risk of developing type 2 
diabetes tend to reduce the consumption of processed foods with high content of sugars, salt 
and trans fats, favoring the consumption of fresh foods like whole grains, legumes, 
vegetables, fruits, nuts, seeds, low-fat dairy, skinless poultry, and fish to provide omega-3 
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fatty acids; in other words, foods with low levels of cholesterol and saturated fats but rich in 
fiber, micronutrients and antioxidants (Melanson, 2008). Daily calorie intake is tailored by 
nutritionists, according to the characteristics of each woman, so they guarantee weight loss 
if recommended and at the same time, an adequate nutrition. It is fundamental to provide 
education on calorie count, food portions, food selection and preparation, reading and 
interpreting labels, since self-monitoring of intake may help them to incorporate the food 
plan in their life-styles and adopt these new behavior patterns (Case et al., 2006).  Uniform 
nutritional recommendations in women with a GDM history are needed. 
3.1.7.2 Physical activity 
Increasing physical activity is paramount in the daily routine of women with previous 
GDM, if there is no contraindication for this after a thorough medical evaluation. The goal is 
to reach a program of aerobic exercises like walking, swimming, dancing, bike riding for 30 
minutes five or more days a week, beginning gradually from 5-10 minutes daily in 
sedentary women. Before and after exercising, stretching exercises must be done for 5-10 
minutes. If this is complemented with strength training using light weights or elastic bands, 
weight loss is increased and muscle tone is improved, having a favorable effect on the 
glucose metabolism (Case et al., 2006).  
3.1.7.3 Non-smoking 
Quitting smoking is recommended in women with previous GDM     (Verier-Mine, 2010), in 
spite of the lack of studies assessing the effects of tobacco in this group with a high risk of 
diabetes and cardiovascular disease. Nonetheless, it has been found that smoking increases 
the risk of diabetes in women, without discerning if they have this family history or not 
(Rimm et al., 1993). 
3.1.7.4 Light to moderate alcohol consumption 
Light to moderate alcohol consumption has been found associated with a minor risk of 
developing type 2 diabetes in middle-aged women and this benefit does not seem to persist 
when alcohol consumption increases (Wannamethee et al., 2003). It is not known if this 
result may be generalized to women with previous GDM, but it results sensible to avoid a 
high level of alcohol consumption due to the possible weight gain and the potential increase 
of type 2 diabetes risk.  
3.1.7.5 Adequate stress management 
Learning and the use of periodic tools to allow managing stress adequately may contribute 
to the goal of keeping healthy women with GDM history. The presence of symptoms of 
depression or excessive anxiety is an indication for assessment and treatment by specialized 
Mental Health professionals, according to each case. 
3.1.8 Pharmacologic intervention 
The use of pharmacologic agents has been explored for preventing or retarding diabetes in 
women with previous GDM. Studies with troglitazone (Buchanan et al., 2002) and 
pioglitazone (Xiang et al., 2006b) have been carried out, demonstrating effectiveness in both 
cases in overweight women. Nonetheless, the former has been discontinued for its 
hepatotoxic effects, and the use of the latter is limited since its prescription is not authorized 
for prevention, due to its safety profile regarding future cardiovascular and osteoporosis 
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disease, and its cost (Verier-Mine, 2010; Kim, 2009: Kim, 2010). When metphormine was 
used in a study, the risk of type 2 diabetes was half reduced in women with overweight and 
obesity (Ratner et al., 2008). Therefore, further research will provide more insight for its 
prescription in clinical practice in combination with a healthy life-style, particularly in obese 
women with glucose intolerance after a GDM pregnancy.  
As shown, an adequate postpartum follow-up program for women with GDM comprises a 
wide range of health-care, clinical-metabolic, gynecological, nutritional, educational, 
psycho-social, physical training, and odontological activities, among others, carried out by 
an interdisciplinary team, in order to prevent or retard progression to diabetes and other 
cardiovascular risk factors, and if this is not attained, to confirm its diagnose as soon as 
possible. 
Unfortunately worldwide, postpartum follow-ups of women with GDM are low. In the 
United States during the first postpartum months, FPG measurements were ordered on 
60.5% women and only completed by 34% (Dinh et al., 2003). In a long cohort of women 
with GDM, 42% were not tested for FPG, the test was not ordered in 21% of them and none 
were tested for OGTT (Dietz et al., 2008). Only 37% were tested for FPG or OGTT with a 
mean of ~ 14 months of postpartum (Smirmakis et al., 2005). In Canada, it has been shown 
that physicians do not order postpartum OGTT, in spite of counting on a publication with 
guidelines based on expert opinions on the subject (Clark et al., 2003). At a Venezuelan 
hospital, in a follow-up program, a 66.19% OGTT adherence after a postpartum period of 
4.04 years + 2.68 was met, with only 17.98% attendance to all basic education sessions (Rivas 
et al., 2010c). Achieving favorable changes in life-styles of women with GDM has resulted 
even more difficult to attain (Stage et al., 2004; Smith et al., 2005), and progression to 
diabetes continues increasing.   
3.2 Changes in quality of life of the population 
Individual approach directed to inform women with GDM on the need of reclassifying their 
metabolic status after delivery, results insufficient for making possible the prevention of 
diabetes and other cardiovascular risk factors. The need to reinforce knowledge and 
motivation in the health care team is evident, as well as the access to health care in this area. 
Moreover, there is a need for stronger research and confrontation on the social determinants 
that make difficult for GDM women, adherence to postpartum follow-up and the adoption of 
healthy life-styles (Hjaltested & Conroy, 2010). Structural measures targeted to the population 
in general, like the ones shown in Table 4, would undoubtedly result in greater benefit. 
 
• Increasing  production, distribution and marketing of fresh foods   
• Promoting the creation and use of public transportation, bicycle lanes, walking lanes  
• Promoting the creation and use  of public sport courts and parks 
• Promoting and protecting breastfeeding 
• Regulating production, distribution and marketing of processed foods rich in trans 
fats, saturated fats, salt  and refined sugars 
• Regulating publicity through communication media of this kind of foods  
• Promoting smoke-free environments 
Table 4. Changes in quality of life of the population 
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4. Conclusion 
After delivery, women with GDM have a high risk of developing diabetes, metabolic 
syndrome, CVD and other clinical disorders that imply a decrease in the quality of life and 
high health-care costs. Thus, over several decades early detection of diabetes and other 
cardiovascular risk factors has been emphasized. For those women who do not show this, it 
is very important to apply strategies directed towards primary prevention like healthy life-
style changes and possible pharmacological intervention, even though further research on 
these results is needed. To meet both objectives, it is paramount to carry out, on one hand, 
life-long postpartum follow-up in women with GDM, and also, to research social 
determinants that affect compliance to these preventive programs and to put into practice 
collective measures that create favorable conditions for its adherence. 
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